Analysis of Nuclear Receptor Coactivator 5 (NCOA5) Messenger RNA Expression and rs2903908 Single Nucleotide Polymorphism of NCOA5 in an Egyptian Cohort with Behçet's Disease: A Single-Center Case-control Study

• Published in: Ocular immunology and inflammation Vol. 30; no. 6; pp. 1436 - 1446
• Main Authors: Koptan, Dina M.T., Rasheed Bahgat, Dina M., Abdelrasool, Asmaa A., Allam, Riham S.H.M., Elgengehy, Fatema T, Abdel Baki, Noha M, Medhat, Basma M
• Format: Journal Article
• Language: English
• Published: Taylor & Francis 18.08.2022
• Subjects: mRNA; NCOA5; Ocular Behçet's disease; real-time polymerase chain reaction; rs2903908
• ISSN: 0927-3948; 1744-5078
• DOI: 10.1080/09273948.2021.1889610

The nuclear receptor coactivator 5 (NCOA5) has been linked to several inflammatory disorders, including Behçet's disease (BD). We evaluated the expression of NCOA5 messenger RNA (mRNA) using real-time reverse transcription-polymerase chain reaction, and analyzed the rs2903908 T > C of NCOA5 using TaqMan allelic discrimination assay in 49 Egyptian BD patients and 50 controls. The NCOA5 mRNA levels were higher in patients compared to controls (p = .02), female patients compared to males (p = .037), and in patients with ocular involvement (p = .049). Non-CC genotype carriers had a higher frequency of articular manifestations compared with CC carriers (p = .047). Genotypes CC + CT were associated with reduced risk of cutaneous involvement (OR = 0.27, p = .04). CC carriers with active BD or cutaneous manifestations displayed significantly lower NCOA5 mRNA expression than TT carriers. Our results demonstrate that NCOA5 is linked to BD clinical findings and activity.